Identification of sulphonamide-tethered N-((triazol-4-yl)methyl)isatin derivatives as inhibitors of SARS-CoV-2 main protease

References

• Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed. 2020;91:157–160.
   PubMedGoogle Scholar
• Mori M, Capasso C, Carta F, Donald WA, Supuran CT. A deadly spillover: SARS-CoV-2 outbreak. Expert Opin Ther Pat. 2020;30(7):481–485.
   PubMed Web of Science ®Google Scholar
• CDC. COVID-19 Treatments and Medications. 2023. https://www.cdc.gov/coronavirus/2019-ncov/your-health/treatments-for-severe-illness.html
   Google Scholar
• CDC. Interim Clinical Considerations for COVID-19 Treatment in Outpatients. 2023. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/outpatient-treatment-overview.html
   Google Scholar
• Supuran CT. Coronaviruses. Expert Opin Ther Pat. 2021;31(4):291–294.
   PubMed Web of Science ®Google Scholar
• Deniz S, Uysal TK, Capasso C, Supuran CT, Ozensoy Guler O. Is carbonic anhydrase inhibition useful as a complementary therapy of Covid-19 infection? J Enzyme Inhib Med Chem. 2021;36(1):1230–1235.
   PubMed Web of Science ®Google Scholar
• Macip G, Garcia-Segura P, Mestres-Truyol J, Saldivar-Espinoza B, Pujadas G, Garcia-Vallvé S. A review of the current landscape of SARS-CoV-2 main protease inhibitors: have we hit the bullseye yet? IJMS. 2021;23(1):259.
   Google Scholar
• Yan S, Wu G. Spatial and temporal roles of SARS-CoV PLpro—A snapshot. Faseb J. 2021;35(1):e21197.
   PubMed Web of Science ®Google Scholar
• Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, Zhang B, Li X, Zhang L, Peng C, et al. Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors. Nature. 2020;582(7811):289–293.
   PubMed Web of Science ®Google Scholar
• Zhong N, Zhang S, Zou P, Chen J, Kang X, Li Z, Liang C, Jin C, Xia B. Without its N-finger, the main protease of severe acute respiratory syndrome coronavirus can form a novel dimer through its C-terminal domain. J Virol. 2008;82(9):4227–4234.
   PubMed Web of Science ®Google Scholar
• a) Capasso C, Nocentini A, Supuran CT. Protease inhibitors targeting the main protease and papain-like protease of coronaviruses. Expert Opin Drug Discov. 2022;17(6):547–557. b) Nocentini A, Capasso C, Supuran CT. Perspectives on the design and discovery of α-ketoamide inhibitors for the treatment of novel coronavirus: where do we stand and where do we go? Expert Opin Drug Discov. 202;(6)547–557.
   PubMedGoogle Scholar
• a) Ma C, Sacco MD, Hurst B, Townsend JA, Hu Y, Szeto T, Zhang X, et al. Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. Cell Res. 2020;30(8):678–692. b) Vuong W, Khan MB, Fischer C, Arutyunova E, Lamer T, Shields J, Saffran HA, et al. Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication. Nat Commun. 11(1)2020;4282.
   PubMed Web of Science ®Google Scholar
• a) Joyce RP, Hu VW and Wang J. The history, mechanism, and perspectives of nirmatrelvir (PF-07321332): an orally bioavailable main protease inhibitor used in combination with ritonavir to reduce COVID-19-related hospitalizations. Med Chem Res. 2022;31(10):1637–1646. b) Singh J, Petter RC, Baillie TA, Whitty A. The resurgence of covalent drugs. Nat. Rev. Drug Discovery. 2011;10:307–317.
   PubMed Web of Science ®Google Scholar
• Bauer RA. Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies. Drug Discov Today. 2015;20(9):1061–1073.
   PubMed Web of Science ®Google Scholar
• Brandao P, Marques C, Burke AJ, Pineiro M. The application of isatin-based multicomponent-reactions in the quest for new bioactive and druglike molecules. Eur J Med Chem. 2021;211:113102.
   PubMed Web of Science ®Google Scholar
• Eldehna WM, El Hassab MA, Abo-Ashour MF, Al-Warhi T, Elaasser MM, Safwat NA, Suliman H, Ahmed MF, Al-Rashood ST, Abdel-Aziz HA, et al. Development of isatin-thiazolo [3, 2-a] benzimidazole hybrids as novel CDK2 inhibitors with potent in vitro apoptotic anti-proliferative activity: synthesis, biological and molecular dynamics investigations. Bioorg Chem. 2021;110:104748.
   PubMed Web of Science ®Google Scholar
• Eldehna WM, Al-Wabli RI, Almutairi MS, Keeton AB, Piazza GA, Abdel-Aziz HA, Attia MI. Synthesis and biological evaluation of certain hydrazonoindolin-2-one derivatives as new potent anti-proliferative agents. J Enzyme Inhib Med Chem. 2018;33(1):867–878.
   PubMed Web of Science ®Google Scholar
• a) Taghour MS, Elkady H, Eldehna WM, El-Deeb NM, Kenawy AM, Elkaeed EB, Alsfouk AA, Alesawy MS, Metwaly AM, and Eissa IH. Design and synthesis of thiazolidine-2, 4-diones hybrids with 1, 2-dihydroquinolones and 2-oxindoles as potential VEGFR-2 inhibitors: in-vitro anticancer evaluation and in-silico studies. J Enzyme Inhib Med Chem. 2022;37(1):1903–1917. b) Eldehna WM, Fares M, Ibrahim HS, Alsherbiny MA, Aly MH, Ghabbour HA, Abdel-Aziz HA. Synthesis and cytotoxic activity of biphenylurea derivatives containing indolin-2-one moieties. " Molecules. 2016;21(6);762.
   PubMed Web of Science ®Google Scholar
• Al-Warhi T, Abo-Ashour MF, Almahli H, Alotaibi OJ, Al-Sanea MM, Al-Ansary GH, Ahmed HY, Elaasser MM, Eldehna WM, Abdel-Aziz HA. Novel [(N-alkyl-3-indolylmethylene) hydrazono] oxindoles arrest cell cycle and induce cell apoptosis by inhibiting CDK2 and Bcl-2: synthesis, biological evaluation and in silico studies. J Enzyme Inhib Med Chem. 2020;35(1):1300–1309.
   PubMed Web of Science ®Google Scholar
• Guo H. Isatin derivatives and their anti-bacterial activities. Eur J Med Chem. 2019;164:678–688.
   PubMed Web of Science ®Google Scholar
• Al-Warhi T, Elimam DM, Elsayed ZM, Abdel-Aziz MM, Maklad RM, Al-Karmalawy AA, Afarinkia K, Abourehab MA, Abdel-Aziz HA, Eldehna WM. Development of novel isatin thiazolyl-pyrazoline hybrids as promising antimicrobials in MDR pathogens. RSC Adv. 2022;12(48):31466–31477.
   PubMed Web of Science ®Google Scholar
• a) Xu Z, Zhang S, Gao C, Fan J, Zhao F, Lv Z-S, Feng L-S. Isatin hybrids and their anti-tuberculosis activity. Chin Chem Lett. 2017;28(2):159–167. b) Abdel-Aziz HA, Ghabbour HA, Eldehna WM, Qabeel MM, Fun H-K. Synthesis, crystal structure, and biological activity of cis/trans amide rotomers of (Z)-N′-(2-Oxoindolin-3-ylidene) formohydrazide. J Chem. 2014;2014:760434.
   Web of Science ®Google Scholar
• Abdelrahman MA, Almahli H, Al-Warhi T, Majrashi TA, Abdel-Aziz MM, Eldehna WM, Said MA. Development of novel isatin-tethered quinolines as anti-tubercular agents against multi and extensively drug-resistant mycobacterium tuberculosis. Molecules. 2022;27(24):8807.
   PubMed Web of Science ®Google Scholar
• Elsayed ZM, Eldehna WM, Abdel-Aziz MM, El Hassab MA, Elkaeed EB, Al-Warhi T, Abdel-Aziz HA, Abou-Seri SM, Mohammed ER. Development of novel isatin–nicotinohydrazide hybrids with potent activity against susceptible/resistant Mycobacterium tuberculosis and bronchitis causing–bacteria. J Enzyme Inhib Med Chem. 2021;36(1):384–393.
   PubMed Web of Science ®Google Scholar
• Chiyanzu I, Clarkson C, Smith PJ, Lehman J, Gut J, Rosenthal PJ, Chibale K. Design, synthesis and anti-plasmodial evaluation in vitro of new 4-aminoquinoline isatin derivatives. Bioorg Med Chem. 2005;13(9):3249–3261.
   PubMed Web of Science ®Google Scholar
• Thakur RK, Joshi P, Baranwal P, Sharma G, Shukla SK, Tripathi R, Tripathi RP. Synthesis and antiplasmodial activity of glyco-conjugate hybrids of phenylhydrazono-indolinones and glycosylated 1, 2, 3-triazolyl-methyl-indoline-2, 3-diones. Eur J Med Chem. 2018;155:764–771.
   PubMed Web of Science ®Google Scholar
• Khatoon S, Aroosh A, Islam A, Kalsoom S, Ahmad F, Hameed S, Abbasi SW, Yasinzai M, Naseer MM. Novel coumarin-isatin hybrids as potent antileishmanial agents: synthesis, in silico and in vitro evaluations. Bioorg Chem. 2021;110:104816.
   PubMed Web of Science ®Google Scholar
• Sabt A, Eldehna WM, Ibrahim TM, Bekhit AA, Batran RZ. New antileishmanial quinoline linked isatin derivatives targeting DHFR-TS and PTR1: design, synthesis, and molecular modeling studies. Eur J Med Chem. 2023;246:114959.
   PubMed Web of Science ®Google Scholar
• Elsaman T, Mohamed MS, Mohamed Eltayib E, Abdel-Aziz HA, Abdalla AE, Munir MU, Mohamed MA. Isatin derivatives as broad-spectrum antiviral agents: the current landscape. Med Chem Res. 2022;31(2):244–273.
   PubMed Web of Science ®Google Scholar
• Pandeya SN, Yogeeswari P, Sriram D, De Clercq E, Pannecouque C, Witvrouw M. Synthesis and screening for anti-HIV activity of some N-Mannich bases of isatin derivatives. Chemotherapy. 1999;45(3):192–196.
   PubMed Web of Science ®Google Scholar
• Banerjee D, Yogeeswari P, Bhat P, Thomas A, Srividya M, Sriram D. Novel isatinyl thiosemicarbazones derivatives as potential molecule to combat HIV-TB co-infection. Eur J Med Chem. 2011;46(1):106–121.
   PubMed Web of Science ®Google Scholar
• Bal TR, Anand B, Yogeeswari P, Sriram D. Synthesis and evaluation of anti-HIV activity of isatin β-thiosemicarbazone derivatives. Bioorg Med Chem Lett. 2005;15(20):4451–4455.
   PubMed Web of Science ®Google Scholar
• De Moraes Gomes PAT, Pena LJ, Leite ACL. Isatin derivatives and their antiviral properties against arboviruses: a review. Mini Rev Med Chem. 2019;19(1):56–62.
   PubMed Web of Science ®Google Scholar
• Mishra P, Kumar A, Mamidi P, Kumar S, Basantray I, Saswat T, Das I, Nayak TK, Chattopadhyay S, Subudhi BB, et al. Inhibition of Chikungunya virus replication by 1-[(2-Methylbenzimidazol-1-yl) Methyl]-2-Oxo-Indolin-3-ylidene]Amino] Thiourea(MBZM-N-IBT). Sci Rep. 2016;6(1):13.
   PubMedGoogle Scholar
• Kang I-J, Wang L-W, Hsu T-A, Yueh A, Lee C-C, Lee Y-C, Lee C-Y, Chao Y-S, Shih S-R, Chern J-H, et al. Isatin-β-thiosemicarbazones as potent herpes simplex virus inhibitors. Bioorg Med Chem Lett. 2011;21(7):1948–1952.
   PubMed Web of Science ®Google Scholar
• Zhang HM, Dai H, Hanson PJ, Li H, Guo H, Ye X, Hemida MG, Wang L, Tong Y, Qiu Y, et al. Antiviral activity of an isatin derivative via induction of PERKNrf2-mediated suppression of cap-independent translation. ACS Chem Biol. 2014;9(4):1015–1024.
   PubMed Web of Science ®Google Scholar
• Pirrung MC, Pansare SV, Das Sarma K, Keith KA, Kern ER. Combinatorial optimization of isatin-β-thiosemicarbazones as anti-poxvirus agents. J Med Chem. 2005;48(8):3045–3050.
   PubMed Web of Science ®Google Scholar
• Selvam P, Murugesh N, Chandramohan M, Sidwell RW, Wandersee MK, Smee DF. Anti-influenza virus activities of 4-[(1,2-dihydro-2-oxo-3H-indol-3- ylidene)amino]-N-(4,6-dimethyl-2-pyrimidin-2-yl)benzenesulphonamide and its derivatives. Antivir Chem Chemother. 2006;17(5):269–274.
   PubMedGoogle Scholar
• Liu W, Zhu H-M, Niu G-J, Shi E-Z, Chen J, Sun B, Chen W-Q, Zhou H-G, Yang C. Synthesis, modification and docking studies of 5-sulfonyl isatin derivatives as SARS-CoV 3C-like protease inhibitors. Bioorg Med Chem. 2014;22(1):292–302.
   PubMed Web of Science ®Google Scholar
• Selvam P, Murgesh N, Chandramohan M, De Clercq E, Keyaerts E, Vijgen L, Maes P, Neyts J, Ranst MV. In vitro antiviral activity of some novel isatin derivatives against HCV and SARS-CoV viruses. Indian J Pharm Sci. 2008;70(1):91–94.
   PubMed Web of Science ®Google Scholar
• Chen L-R, Wang Y-C, Lin YW, Chou S-Y, Chen S-F, Liu LT, Wu Y-T, Kuo C-J, Shieh-Shung Chen T, Juang S-H. Synthesis and evaluation of isatin derivatives as effective SARS coronavirus 3CL protease inhibitors. Bioorg Med Chem Lett. 2005;15(12):3058–3062.
   PubMed Web of Science ®Google Scholar
• Zhou L, Liu Y, Zhang W, Wei P, Huang C, Pei J, Yuan Y, Lai L. Isatin compounds as noncovalent SARS coronavirus 3C-like protease inhibitors. J Med Chem. 2006;49(12):3440–3443.
   PubMed Web of Science ®Google Scholar
• Liu P, Liu H, Sun Q, Liang H, Li C, Deng X, Liu Y, Lai L. Potent inhibitors of SARS-CoV-2 3C-like protease derived from N-substituted isatin compounds. Eur J Med Chem. 2020;206:112702.
   PubMed Web of Science ®Google Scholar
• ElNaggar MH, Abdelwahab GM, Kutkat O, GabAllah M, Ali MA, El-Metwally ME, Sayed AM, Abdelmohsen UR, Khalil AT. Aurasperone A inhibits SARS CoV-2 in vitro: an integrated in vitro and in silico study. Mar Drugs. 2022;20(3):179.
   PubMed Web of Science ®Google Scholar
• Elsbaey M, Ibrahim MAA, Bar FA, Elgazar AA. Chemical constituents from coconut waste and their in-silico evaluation as potential antiviral agents against SARS-CoV-2. S Afr J Bot. 2021;141:278–289.
   PubMed Web of Science ®Google Scholar
• Elimam DM, Elgazar AA, El-Senduny FF, El-Domany RA, Badria FA, Eldehna WM. Natural inspired piperine-based ureas and amides as novel antitumor agents towards breast cancer. J Enzyme Inhib Med Chem. 2022;37(1):39–50.
   PubMed Web of Science ®Google Scholar
• Al-Sanea MM, Hamdi A, Mohamed AAB, El-Shafey HW, Moustafa M, Elgazar AA, Eldehna WM, Ur Rahman H, Parambi DGT, Elbargisy RM, et al. New benzothiazole hybrids as potential VEGFR-2 inhibitors: design, synthesis, anticancer evaluation, and in silico study. J Enzyme Inhib Med Chem. 2023;38(1):2166036.
   PubMed Web of Science ®Google Scholar
• Othman DI, Hamdi A, Tawfik SS, Elgazar AA, Mostafa AS. Identification of new benzimidazole-triazole hybrids as anticancer agents: multi-target recognition, in vitro and in silico studies. J Enzyme Inhib Med Chem. 2023;38(1):2166037.
   PubMed Web of Science ®Google Scholar
• Elbadawi MM, Eldehna WM, Nocentini A, Abo-Ashour MF, Elkaeed EB, Abdelgawad MA, Alharbi KS, Abdel-Aziz HA, Supuran CT, Gratteri P, et al. Identification of N-phenyl-2-(phenylsulfonyl) acetamides/propanamides as new SLC-0111 analogues: synthesis and evaluation of the carbonic anhydrase inhibitory activities. Eur J Med Chem. 2021;218:113360.
   PubMed Web of Science ®Google Scholar
• An R, Lin B, Zhao S, Cao C, Wang Y, Cheng X, Liu Y, Guo M, Xu H, Wang Y, et al. Discovery of novel artemisinin-sulfonamide hybrids as potential carbonic anhydrase IX inhibitors with improved antiproliferative activities. Bioorg Chem. 2020;104:104347.
   PubMed Web of Science ®Google Scholar
• El‐Sayed HA, Moustafa AH, Masry AA, Amer AM, Mohammed SM. An efficient synthesis of 4, 6‐diarylnicotinonitrile‐acetamide hybrids via 1, 2, 3‐triazole linker as multitarget microbial inhibitors. J Heterocyclic Chem. 2022;59(2):275–285.
   Web of Science ®Google Scholar
• Firoozpour L, Gao L, Moghimi S, Pasalar P, Davoodi J, Wang M-W, Rezaei Z, Dadgar A, Yahyavi H, Amanlou M, et al. Efficient synthesis, biological evaluation, and docking study of Isatin based derivatives as caspase inhibitors. J Enzyme Inhib Med Chem. 2020;35(1):1674–1684.
   PubMed Web of Science ®Google Scholar
• Tri NM, Thanh ND, Ha LN, Anh DTT, Toan VN, Giang NTK. Study on synthesis of some substituted N-propargyl isatins by propargylation reaction of corresponding isatins using potassium carbonate as base under ultrasound-and microwave-assisted conditions. Chem Pap. 2021;75(9):4793–4801.
   Web of Science ®Google Scholar
• Day J, Uroos M, Castledine RA, Lewis W, McKeever-Abbas B, Dowden J. Alkaloid inspired spirocyclic oxindoles from 1, 3-dipolar cycloaddition of pyridinium ylides. Org Biomol Chem. 2013;11(38):6502–6509.
   PubMed Web of Science ®Google Scholar
• Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferatio and cytotoxicity assays. J Immunol Methods. 1983;65(1-2) :55–63.
   PubMed Web of Science ®Google Scholar
• Abd-Alla HI, Kutkat O, Sweelam H-t. M, Eldehna WM, Mostafa MA, Ibrahim MT, Moatasim Y, GabAllah M, Al-Karmalawy AA. Investigating the potential anti-SARS-CoV-2 and anti-MERS-CoV activities of yellow necklacepod among three selected medicinal plants: extraction, Isolation, identification, in vitro, modes of action, and molecular docking studies. Metabolites. 2022;12(11):1109.
   PubMed Web of Science ®Google Scholar
• Al-Karmalawy AA, El-Gamil DS, El-Shesheny R, Sharaky M, Alnajjar R, Kutkat O, Moatasim Y, Elagawany M, Al-Rashood ST, Binjubair FA, et al. Design and statistical optimisation of emulsomal nanoparticles for improved anti-SARS-CoV-2 activity of N-(5-nitrothiazol-2-yl)-carboxamido candidates: in vitro and in silico studies. J Enzyme Inhib Med Chem. 2023;38(1):2202357.
   PubMed Web of Science ®Google Scholar
• Elebeedy D, Elkhatib WF, Kandeil A, Ghanem A, Kutkat O, Alnajjar R, Saleh MA, Maksoud AIAE, Badawy I, Al-Karmalawy AA. Anti-SARS-CoV-2 activities of tanshinone IIA, carnosic acid, rosmarinic acid, salvianolic acid, baicalein, and glycyrrhetinic acid between computational and in vitro insights. RSC Adv. 2021;11(47):29267–29286.
   PubMed Web of Science ®Google Scholar
• Abo Elmaaty A, Eldehna W, Khattab M, Kutkat O, Alnajjar R, El-Taweel A, Al-Rashood S, Abourehab M, Binjubair F, Saleh M, et al. Anticoagulants as potential SARS-CoV-2 Mpro inhibitors for COVID-19 Patients: in vitro, molecular docking, molecular dynamics, DFT, and SAR studies. IJMS. 2022;23(20):12235.
   Google Scholar
• Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31(2):455–461.
   PubMed Web of Science ®Google Scholar
• Gao S, Sylvester K, Song L, Claff T, Jing L, Woodson M, Weiße RH, Cheng Y, Schäkel L, Petry M, et al. Discovery and crystallographic studies of trisubstituted piperazine derivatives as non-covalent SARS-CoV-2 main protease inhibitors with high target specificity and low toxicity. J Med Chem. 2022;65(19):13343–13364.
   PubMed Web of Science ®Google Scholar
• Abraham MJ, Murtola T, Schulz R, Páll S, Smith JC, Hess B, Lindahl E. GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX. 2015;1-2:19–25.
   Google Scholar
• Schüttelkopf AW, van Aalten DMF. PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr D Biol Crystallogr. 2004;60(Pt 8):1355–1363.
   PubMedGoogle Scholar
• Hassab MAE, Fares M, Amin MKA-H, Al-Rashood ST, Alharbi A, Eskandrani RO, Alkahtani HM, Eldehna WM. Toward the identification of potential α-ketoamide covalent inhibitors for SARS-CoV-2 main protease: fragment-based drug design and MM-PBSA calculations. Processes. 2021;9(6):1004.
   Web of Science ®Google Scholar
• El Hassab MA, Shoun AA, Al-Rashood ST, Al-Warhi T, Eldehna WM. Identification of a new potential SARS-COV-2 RNA-dependent RNA polymerase inhibitor via combining fragment-based drug design, docking, molecular dynamics, and MM-PBSA calculations. Front Chem. 2020;8:915.
   Web of Science ®Google Scholar
• El Hassab MA, Ibrahim TM, Al-Rashood ST, Alharbi A, Eskandrani RO, Eldehna WM. In silico identification of novel SARS-COV-2 2'-O-methyltransferase (nsp16) inhibitors: structure-based virtual screening, molecular dynamics simulation and MM-PBSA approaches. J Enzyme Inhib Med Chem. 2021;36(1):727–736.
   PubMed Web of Science ®Google Scholar
• El Hassab MA, Ibrahim TM, Shoun AA, Al-Rashood ST, Alkahtani HM, Alharbi A, Eskandrani RO, Eldehna WM. In silico identification of potential SARS COV-2 2′-O-methyltransferase inhibitor: fragment-based screening approach and MM-PBSA calculations. RSC Adv. 2021;11(26):16026–16033.
   PubMed Web of Science ®Google Scholar